Partner Therapeutics, Inc. (PTx)
19 Muzzey Street
About Partner Therapeutics, Inc. (PTx)
We're all in for the fight against cancer. Partner Therapeutics (PTx) is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients. We are united in our passion for improving the treatment of cancer and our desire to make a meaningful contribution to outcomes.
The patient is number one. We believe that being a cancer company begins and ends with the patient. We strive to support patient needs throughout their treatment journey to help them make the treatment choices that are right for them and their loved ones.
2 articles with Partner Therapeutics, Inc. (PTx)
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Partner Therapeutics Receives FDA Orphan Drug Designation for Leukine® for the Treatment of Pulmonary Alveolar Proteinosis
Partner Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine®.